Applicant, as named in the Orange Book

Harrow Eye

Next listed expiry: Nevanac on 31 Jan 2027. 9 products with live protection, 7 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Nevanac nepafenac	nepafenac	021862	31 Jan 2027	patent, carve-out possible
Tobradex St dexamethasone; tobramycin	dexamethasone; tobramycin	050818	3 Aug 2028	patent
Verkazia cyclosporine	cyclosporine	214965	2 Jun 2029	patent
Triesence triamcinolone acetonide	triamcinolone acetonide	022048	17 Dec 2029	patent
Ilevro nepafenac	nepafenac	203491	31 Mar 2032	patent
Zerviate cetirizine hydrochloride	cetirizine hydrochloride	208694	9 Jan 2033	patent
Byqlovi clobetasol propionate	clobetasol propionate	218158	9 May 2036	patent
Iheezo chloroprocaine hydrochloride	chloroprocaine hydrochloride	216227	14 May 2039	patent
Vevye cyclosporine	cyclosporine	217469	1 Apr 2042	patent

Recent events

25 Oct 2026Verkazia · Generic approved 28 Nov 2025
25 Oct 2026Verkazia · Generic approved 1 Jun 2026
25 Oct 2026Verkazia · Generic approved 21 Jan 2026
24 Oct 2026Nevanac · Enters 12-month window basis: patent, carve-out possible31 Jan 2027

Products without listed protection (7)

Drug	Ingredient	NDA	Earliest generic entry	Basis
Flarex fluorometholone acetate	fluorometholone acetate	019079	open now	no listed protection
Iopidine apraclonidine hydrochloride	apraclonidine hydrochloride	019779	open now	no listed protection
Iopidine apraclonidine hydrochloride	apraclonidine hydrochloride	020258	open now	no listed protection
Maxidex dexamethasone	dexamethasone	013422	open now	no listed protection
Maxitrol dexamethasone; neomycin sulfate; polymyxin b sulfate	dexamethasone; neomycin sulfate; polymyxin b sulfate	050023	open now	no listed protection
Natacyn natamycin	natamycin	050514	open now	no listed protection
Vigamox moxifloxacin hydrochloride	moxifloxacin hydrochloride	021598	open now	no listed protection